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Molecular surveillance of multidrug-resistant tuberculo-
sis (MDR TB) was implemented in Europe as case reporting 
in 2005. For all new MDR TB cases detected from January 
2003  through  June  2007,  countries  reported  case-based 
epidemiologic data and DNA fingerprint patterns of MDR TB 
strains when available. International clusters were detected 
and  analyzed.  From  2003  through  mid-2007  in  Europe, 
2,494 cases of MDR TB were reported from 24 European 
countries. Epidemiologic and molecular data were linked for 
593 (39%) cases, and 672 insertion sequence 6110 DNA 
fingerprint  patterns  were  reported  from  19  countries.  Of 
these patterns, 288 (43%) belonged to 18 European clus-
ters; 7 clusters (242/288 cases, 84%) were characterized 
by strains of the Beijing genotype family, including the larg-
est cluster (175/288 cases, 61%). Both clustering and the 
Beijing genotype were associated with strains originating 
in eastern European countries. Molecular cluster detection 
contributes to identification of transmission profile, risk fac-
tors, and control measures. 
P
revalence  of  multidrug-resistant  tuberculosis  (MDR 
TB), i.e., TB resistant to at least rifampin and isoniazid, 
is increasing, particularly in some areas of Europe (1). From 
1999 through 2002, the median prevalence of MDR TB in 
new case-patients was at critical levels (>6.5%) in specific 
regions of the world, including the Baltic states and other 
eastern European countries (2). In 2004, the Russian Feder-
ation, China, and India accounted for 62% of the estimated 
global MDR TB cases (3). The increases in prevalence and 
incidence of MDR TB are most likely caused by inadequate 
treatment regimens (4). Recently, public health awareness 
about MDR TB has been reenforced by the occurrence of 
extensively drug-resistant (XDR) TB outbreaks associated 
with HIV, particularly in South Africa (5,6). Surveillance 
of drug resistance, based on annual case reporting of drug 
susceptibility tests, has been ongoing in Europe since 1998 
and includes annual reporting of MDR TB cases after the 
start of treatment (7). In the 1990s, molecular methods be-
came available and have allowed researchers to study is-
sues in the epidemiology of TB (8). Strains of the Myco-
bacterium tuberculosis Beijing genotype, which constitute 
a group of genetically closely related strains (9), have been 
associated with high levels of drug resistance in countries 
of the former Soviet Union (FSU), including Latvia (10) 
and Estonia (11); these strains have been of low prevalence 
(6%–7%) in Western Europe (12).
Public health officials are concerned about possible 
emergence  and  transmission  of  MDR  TB  strains  across 
Europe (cross-border migration), but no system is in place 
to identify whether MDR TB strains are shared (clustered) 
among European countries. Risk factors for possible clus-
tering have yet to be determined. When the drug resistance 
surveillance project began, data on MDR TB cases were 
reported in aggregated format at the European level and 
could not be linked to molecular data identified from in-
dividual MDR TB cases. Also, a need existed to further 
identify the association between Beijing genotype strains 
or M. tuberculosis strains of other genotypes and MDR TB 
in Europe.
Molecular surveillance of MDR TB was developed in 
Europe in recent years, first, in a pilot phase as part of the 
European Concerted Action on Tuberculosis project and, 
prospectively, since 2005, with the MDR TB project pre-
sented in this paper (13). The objectives of this project were 
to identify molecular clusters of MDR TB cases reported in 
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>1 European country, to describe epidemiologic risk fac-
tors associated with MDR TB cases, and to initiate cluster 
investigations at the national level to prevent cross-border 
transmission.
In this article, based on surveillance data, we describe 
the main epidemiologic and demographic characteristics of 
MDR TB cases reported from January 2003 through June 
2007 in 24 European countries. We also describe character-
istics of the main European clusters and identify risk fac-
tors for clustering and association with the Beijing strain of 
M. tuberculosis.
Materials and Methods
Data Collection and Management
In 2005, all 53 countries of the World Health Organi-
zation’s European region were invited to participate in the 
MDR TB surveillance project by Euro TB and the National 
Institute for Public Health and the Environment (RIVM). 
Countries were encouraged to provide both epidemiolog-
ic and genotyping data on MDR TB cases reported since 
January 1, 2003. However, countries that could provide 
only epidemiologic data were also included in the surveil-
lance project. National surveillance institutions sent quar-
terly updates of individual and anonymous data on MDR 
TB cases reported since 2003 to EuroTB, according to a 
standardized data file specification (www.eurotb.org/mdr_
tb_surveillance/pdf/DFS_NSI_short.pdf). Each patient had 
a unique record identifier by country. Common definitions 
of variables were used by participating countries, including 
demographic, clinical, and genotyping information. In 18 
countries, the country of origin was defined as the coun-
try of birth. Because of confidentiality constraints, country 
of birth was not reported for some countries. Country of 
citizenship was used to qualify the origin of patients for 2 
countries. Either country of birth or country of citizenship 
was used in 3 countries, and information on geographic 
origin was unavailable in 1 country. A patient had to be 
reported again (with a new identifier) when a new MDR M. 
tuberculosis isolate was obtained >24 months after the pre-
viously reported MDR TB isolate. However, the possibility 
of a case being reported twice in the same country or in 2 
countries was low.
National  laboratories  sent  insertion  sequence  (IS) 
6110  restriction  fragment  length  polymorphism  (RFLP) 
patterns from available MDR TB strains collected since 
2003 to the RIVM every 3 months, either as a Bionumerics 
bundle  (Applied  Maths,  Sint-Maartens-Latem,  Belgium) 
or as a scanned image (14). To be included in the project, 
laboratories had to perform drug susceptibility testing and 
participate in an international quality assurance program. 
For quality assurance, either participating laboratories rep-
resented supranational reference laboratories of the World 
Health Organization and the International Union against 
Tuberculosis  and  Lung  Disease  and  participated  in  the 
yearly proficiency testing for isoniazid, rifampin, strepto-
mycin, and ethambutol (15,16), or laboratories had their 
external quality assurance conducted by such a reference 
laboratory. For 1 country, drug susceptibility testing was 
performed in a laboratory abroad. More details (e.g., on 
drug susceptibility test methods) can be found in the 2006 
EuroTB report (17).
European cluster information was communicated by 
the RIVM (Bilthoven, the Netherlands) to EuroTB on a 
quarterly basis. The final database was maintained by Eu-
roTB and included 3 sections: A) demographic and clinical 
variables, B) cluster information on the basis of molecular 
patterns at the country level, and C) European cluster in-
formation. Data from sections A and B were matched ac-
cording to a patient code; data from sections B and C were 
matched  using  the  strain  code  attributed  at  the  national 
level.
Analysis of Genotyping Data
IS6110  RFLP  was  the  recommended  genotyping 
method (18) to report IS6110 RFLP patterns to RIVM. For 
most countries, genotyping was performed locally; for 2 
countries, genotyping was performed at RIVM. A Euro-
pean cluster was defined as >2 MDR TB cases with M. tu-
berculosis isolates that shared identical IS6110 RFLP pat-
terns in >2 countries (18). A national cluster included cases 
diagnosed in a single country. Determination of a national 
cluster (a cluster including MDR TB cases diagnosed in 
1 participating country) could be based on 3 typing meth-
ods: IS6110 RFLP typing (18), spoligotyping (19), and/or 
typing that used mycobacterial interspersed repetitive units 
with variable numbers of tandem repeats (20).
In each laboratory, quality control of the molecular 
typing  practices  and  computer-assisted  analysis  was  in-
cluded as described in the standardized methods (14). The 
DNA fingerprint patterns of MDR TB strains received at 
the RIVM were submitted to the molecular database man-
aged by the RIVM (MDRTBase) by using the Bionumerics 
software (Applied Maths), and the database manager per-
formed a quality check. The IS6110 RFLP patterns newly 
added to the MDRTBase were then compared with all other 
patterns stored in this database. The MDR TB strains were 
classified as clustered (included in a European cluster) or 
“unique” (not included in a European cluster). In addition 
to specifying European cluster reports, the database man-
ager also specified strains belonging to the Beijing geno-
type family of M. tuberculosis by compariing them with the 
19 reference RFLP patterns of Beijing strains described by 
Kremer et al. (21).
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Statistical Data Analysis
Factors associated with clustering or infection with a 
Beijing genotype strain were determined by the unadjusted 
and adjusted logistic regression model using SAS software 
(SAS Institute, Cary, NC, USA). The explanatory variables 
were demographic (sex, age, origin) and clinical (pulmo-
nary vs. extrapulmonary TB, TB history) characteristics 
of MDR TB cases. XDR TB was studied as an explana-
tory variable for patients with drug susceptibility results 
meeting the definition of XDR TB (22) in both cluster and 
strain analyses. The proportion of clustering among Bei-
jing strains was compared with the proportion of clustering 
among strains of other genotypes.
Because  of  the  limited  numbers  per  category,  “un-
known”  categories  were  removed  from  all  variables  in-
cluded in the model, as was the age category “<15 years” 
and the category “other” for the variable country of ori-
gin. Analyses, including clustering and the XDR variable, 
were performed in the univariate model only because of the 
variables’ strong association with origin in the Baltic states 
(χ2 97.1, p<0.001) and other countries of the FSU (χ2 20.5, 
p<0.001).
Results
Country Participation, Number of MDR TB Cases  
Reported, and Clustering of MDR TB Cases 
Twenty-four countries from the European Union and 
western Europe plus Croatia and Macedonia participated 
in the MDR TB project (Table 1). Epidemiologic data on 
2,494 MDR TB cases reported from January 2003 through 
July 2007 were sent to EuroTB. The Baltic states (Estonia, 
Latvia, and Lithuania) reported 1,616 cases, representing 
65% of total cases. In some countries, epidemiologic data 
were reported for <3 years (Germany, Lithuania, Poland, 
Romania, and Spain).
Laboratories from 19 countries sent 672 IS6110 RFLP 
patterns to the RIVM, 593 of which also had epidemiologic 
information  and  were  linked  to  the  epidemiologic  data-
base maintained by EuroTB (Table 1; Figure 1). Linkage 
of molecular and epidemiologic data was not possible for 
data from the United Kingdom and for data on a few cases 
from 6 other countries. The average proportion of MDR 
TB cases documented with both epidemiologic and geno-
typing data in 18 countries was 593/1,523 (39%), varying 
from 9% to 100%. After we removed data from 2 countries 
with low data completeness for genotypes (Germany and 
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Table 1. Number of diagnosed MDR TB cases reported in 24 European countries and number and proportion of genotyped MDR TB 
strains, as reported to the MDR TB surveillance project, by year, January 2003 through June 2007* 
No. cases reported  No. genotyped strains reported 
Country  2003 2004 2005 2006 and 2007  Total All With data (% total cases) 
Belgium† (EU)  9 14 7 1 31 15 15 (48) 
Croatia 2 1 2 – 5 5 5 (100)
Cyprus (EU)  2 0 1 – 3 – –
Czech Republic (EU)  15 13 4 6 38 11 5 (13) 
Denmark (EU)  0 0 5 – 5 4 4 (80) 
Estonia (EU)  96 80 72 – 248 228 228 (92) 
Finland (EU)  3 0 2 2 7 7 7 (100) 
France (EU)  53 53 46 – 152 63 63 (41) 
Germany (EU)  – – 101 – 101 17 16 (16) 
Ireland (EU)  1 2 3 2 8 3 3 (38) 
Israel 18 15 12 – 45 39 39 (87)
Italy (EU)  45 18 17 3 83 25 25 (30) 
Latvia (EU)  188 208 160 156 712 – –
Lithuania (EU)  – 318 338 – 656 56 56 (9) 
Macedonia, FYR  4 1 6 4 15 – –
Netherlands (EU)  17 10 7 – 34 44 34 (100) 
Norway (EU)  2 4 3 2 11 7 3 (27) 
Poland (EU)  – – 1 16 17 – –
Romania (EU)  – 25 25 – 50 – –
Slovenia (EU)  1 0 1 1 3 2 2 (67) 
Spain (EU)  – 28 22 – 50 50 50 (100) 
Sweden (EU)  7 7 4 3 21 21 18 (86) 
Switzerland  9 9 3 4 25 25 20 (80)
United Kingdom (EU)  68 52 54 – 174 50 –
Total 540 858 896 200 2,494 672 593 (39) 
*MDR TB, multidrug-resistant tuberculosis; EU, European Union; –, not available; FYR, Former Yugoslav Republic of Macedonia.            
†Includes only cases detected at the start of treatment. Clusters of MDR TB Cases, Europe 
Lithuania), we found that the average proportion of MDR 
TB cases with both epidemiologic and genotyping data was 
68%. Individual data on second-line drug tests for 2 to 5 
second-line drugs included in the XDR TB definition (22) 
were reported for 1,302 cases by 16 countries from January 
2003 through July 2007 (Figure 1).
Of the 672 MDR TB strains with IS6110 RFLP pat-
terns reported, 288 (43%) were identified as belonging to 
European clusters (Table 2; Figure 1). The proportion of 
MDR TB strains included in European clusters was <20% 
in  7  countries  (Croatia,  France,  Italy,  Slovenia,  Spain, 
Switzerland, and the United Kingdom). A large proportion 
(38%) of the RFLP patterns submitted to the molecular da-
tabase originated from Estonia, where 80% (183/228) of 
the strains clustered. The number of MDR TB strains iden-
tified in national clusters was 170 among 330 strains (51%) 
reported in 13 of the 19 countries with genotyping data. In 
these 13 countries, the proportion of intercountry clustering 
was 28%.
Description of MDR TB Clusters
Eighteen  distinct  European  clusters  (range  2–175 
cases) were identified in 16 countries (Table 3). Clusters 
E0051, E0054, E0055, E0057, E0063, E0066, and E0069 
were characterized by Beijing genotype strains, comprising 
242/288 (84%) clustered MDR TB cases. The characteris-
tics of the 4 largest clusters are described below.
Cluster E0051
The  largest  cluster,  E0051,  consisted  of  175  MDR 
TB  cases  reported  in  12  countries.  Of  these  175  cases, 
148 (85%) were reported in Estonia. No significant differ-
ences were found between case-patients included in cluster 
E0051 and those included in other clusters for sex, age cat-
egory, TB history, and XDR TB (χ2 test, p>0.05). A large 
proportion (119/148, 81%) of the case-patients reported in 
Estonia also originated from this country (Figure 2). The 
proportion of case-patients who had never had TB (either 
no  diagnosis  or  no  treatment)  was  high  (90/148,  61%). 
Thirty-three cases (22%) were identified as XDR TB. Eight 
of the 175 case-patients in cluster E0051 were reported in 
Israel, and all 8 originated from FSU countries (6 from the 
Russian Federation, 1 from Georgia, and 1 from Kazakh-
stan); all were pulmonary patients and alive at the time of 
diagnosis. No information was available on previous TB 
diagnosis or treatment. None of the 8 MDR TB cases re-
ported in Israel were XDR. The 6 case-patients reported in 
Lithuania also originated from that country. Five of these 
case-patients were known to have had a previous diagnosis 
of TB; XDR TB was not diagnosed in these case-patients. 
The 3 case-patients reported in Belgium originated from 
the Russian Federation (n = 2) and from Georgia. Their TB 
history was unknown. For the 2 case-patients reported in 
Finland, origin was unknown. One of the 2 case-patients 
reported in Switzerland was from Armenia; the origin of 
the other case-patient was unknown. The 2 case-patients 
reported in the Netherlands and Sweden originated from 
the Russian Federation.
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2,494 MDR TB cases 
reported in 24 countries
288 MDR TB strains
in European clusters 
(19 countries)
Original data 
sets
Subgroups for analysis
in 16 countries*
RFA in 
16 countries*
500 MDR TB strains to 
be analyzed for Beijing 
genotype
392 cases to be tested
for XDR in clustering
and Beijing RFA
250 clustered strains
in clustering RFA
284 Beijing strains
in Beijing RFA
593 MDR TB cases 
with epi + genotyping
data in 18 countries
1,302 MDR TB cases 
with SLD DST meeting 
XDR definition
672 MDR TB strains
with genotyping data 
in 19 countries
521 MDR TB cases with
epi + genotyping data
Figure 1. Description of MDR TB cases in Europe selected for data 
analysis, January 2003–July 2007. RFA does not include data from 
Germany and Lithuania. MDR TB, multidrug-resistant tuberculosis; 
SLD,  second-line  drug;  DST,  drug-susceptibility  test;  RFA,  risk 
factor analysis. *Countries: Belgium, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, Ireland, Israel, Lithuania, the 
Netherlands, Norway, Spain, Sweden, Switzerland, and the United 
Kingdom.
Table 2. Number of genotyped MDR TB strains in 19 European 
countries, with cluster status, by country, January 2003 through 
June 2007* 
Country 
Genotyped 
strains 
European
clusters,
no. (%) 
National
clusters,
no. (%) 
Belgium† 15 7 (47)  7 (47) 
Croatia 5 0 5 (100)
Czech Republic  11 3 (27)  –
Denmark 4 1 (25)  1 (25) 
Estonia 228 183 (80)  –
Finland 7 3 (43)  5 (71) 
France 63 10 (16)  24 (38) 
Germany  17 8 (47)  9 (53) 
Ireland 3 1 (33) –
Israel 39 18 (46)  32 (82) 
Italy  25 0 –
Lithuania 56 18 (32)  43 (77) 
Netherlands 44 11 (25)  17 (39) 
Norway  7 2 (29)  2 (29) 
Slovenia 2 0 2 (100)
Spain 50 7 (14)  14 (28) 
Sweden  21 9 (43)  9 (43) 
Switzerland  25 3 (12) –
United Kingdom  50 4 (8)  –
Total 672 288 (43)  170 (51) 
*MDR TB, multidrug-resistant tuberculosis; –, not available.  
†Includes only cases detected at the start of treatment. RESEARCH
Cluster E0054
Twenty-eight of the 33 case-patients included in the 
second largest cluster, E0054, had a known origin. All but 
1 (from Israel) originated from FSU countries (17 originat-
ing and reported in Estonia).
Cluster E0055
Eighteen of the 22 case-patients included in cluster 
E0055 had a known origin; 13 were reported in Estonia, 2 
in Israel, 1 in Lithuania, 1 in the Netherlands, and 1 in Swe-
den. All originated from FSU countries, except the case-
patient in the Netherlands, who originated from Sri Lanka.
Cluster E0053
Cluster E0053 (non-Beijing) included 10 cases with 
known origin. Five case-patients originated from the coun-
try of report, and 5 others originated from Africa (2 from 
Côte d’Ivoire, 2 from Nigeria, and 1 from Mali). Because 
this cluster was characterized by an M. tuberculosis strain 
containing 4 copies of IS6110, it could possibly be sub-
divided if additional DNA typing methods are used. As 
indicated in Table 3, two other clusters were also caused 
by low–copy-number strains: clusters E0070 (4 cases) and 
E0067 (3 cases).
Risk Factors for Clustering Among MDR TB Isolates
Risk factors for clustering were analyzed for 521 cases 
documented with both molecular and epidemiologic data 
reported  by  16  countries.  Lithuania  and  Germany  were 
excluded from this analysis due to incomplete genotyping 
data. Among these 521 cases, 250 (48%) belonged to Euro-
pean clusters and 271 (52%) had isolates with unique DNA 
fingerprint patterns (Figure 1). The results of univariate and 
multiple logistic regression analyses to determine factors 
associated with clustering are presented in Table 4.
Univariate analysis showed that origin from the Baltic 
states or other FSU countries, age category 45–64 years, 
and  pulmonary  tuberculosis  were  significantly  associ-
ated with clustering. Among these variables, only origin 
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Table 3. Number of multidrug-resistant tuberculosis strains in 16 European countries, by cluster and by country, January 2003 through 
June 2007 
Cluster no. (E00--) 
Country  51* 54* 55* 53† 64 68 60 66* 70† 57* 63* 67† 56 59 61 62 65 69* Total 
Estonia 148 18 13 2 2 183
Israel 8 3 2 2 2 1 18
Lithuania 6 3 1 4 2 1 1 18
Netherlands 1 4 1 2 1 1 1 11
France 6 1 1 1 1 10
United Kingdom  1 1 1 1 4
Sweden  1 2 1 1 1 1 1 1 9
Germany  1 3 2 1 1 8
Belgium 3 2 1 1 7
Spain 5 1 1 7
Switzerland  2 1 3
Czech Republic  2 1 3
Finland 2 1 3
Norway  1  1  2 
Denmark  1  1 
Ireland 1 1
Total 175 33 22 12 6 6 5 4 4 3 3 3 2 2 2 2 2 2 288
*Caused by Beijing genotype strains. 
†Caused by low-copy strains; the insertion sequence 6110 restriction fragment length polymorphism pattern of cluster E0053 consisted of 4 bands; 
cluster E0070, 3 bands; and cluster E0067, 1 band. 
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Figure  2. Origin  and  country  of report for the largest  European 
cluster of multidrug-resistant tuberculosis cases (cluster E0051). 
The cases were reported in 12 European countries (see Table 3). 
Five countries did not have information about the origin of the cases 
reported there. For cases reported in the countries shaded in dark 
gray, the base of the arrow shows where case-patients originated 
(1 case per arrow, unless otherwise indicated). The 6 case-patients 
reported in Lithuania were also born there. Of the 148 case-patients 
reported in Estonia, 119 were also born there. The remaining case-
patients  reported  in  Estonia  were  originally  from  Russia  (13), 
Belarus (6), Ukraine (5), Lithuania (1) and Turkmenistan (1); origin 
was unknown for 3 case-patients.Clusters of MDR TB Cases, Europe 
from the Baltic states (adjusted odds ratio [OR] 25.1, 95%   
confidence interval [CI] 9.9–64.0) or other FSU countries 
(adjusted OR 8.7, 95% CI 3.2–23.2) remained strongly as-
sociated with clustering in the multivariate model. The pro-
portion of XDR TB cases was significantly higher among 
clustered strains than among unique strains (OR 4.1, 95% 
CI 1.9–8.7).
Risk Factors for TB Characterized by Strains of the 
Beijing Genotype among MDR TB Cases 
Analysis to identify Beijing genotype strains was pos-
sible for 500 of the 521 MDR TB strains with both epi-
demiologic and genotyping data (data from Germany and 
Lithuania were excluded). Of these 500 strains, 284 (57%) 
were  identified  as  the  Beijing  genotype  and  216  (43%) 
were non-Beijing genotypes (Figure 1). Univariate analy-
sis demonstrated that origin from the Baltic states or other 
FSU countries, age categories 45–64 years and >65 years, 
and  pulmonary  TB  were  significantly  associated  with 
strains of the Beijing genotype (Table 5). Among these 
variables, origin from Baltic states and other FSU coun-
tries remained strongly associated with Beijing genotype 
strains in the multivariate analysis. Proportions of cluster-
ing and XDR TB were significantly higher among Beijing 
strains than among other genotype strains, (OR 19.6, 95% 
CI 12.3–31.2, and OR 5.5, 95% CI 2.1–14.3, respective-
ly). After exclusion of the largest cluster, E0051 (n = 166 
cases with epidemiologic data), characterized by a Beijing 
strain, the association between clustering and the Beijing 
genotype was 5× less but still quite strong for 334 MDR TB 
cases with genotyping data (OR 4.5, 95% CI 2.7–7.6).
Discussion
Molecular surveillance of MDR TB cases in Europe 
showed  several  large  molecular  clusters  (also  including 
XDR TB cases). The largest cluster (175 cases) was mainly 
localized in Estonia (information to be completed for Lith-
uania and Latvia). Origin from the Baltic states and other 
FSU countries was strongly associated with clustering. The 
proportion of XDR TB was high among clustered strains. 
The high proportion of MDR TB case-patients without re-
ported TB history suggests circulation of primary MDR 
strains in these countries. Three of the 18 European clus-
ters were caused by low-copy strains and may represent 
false clustering. However, because these clusters consisted 
of only a few cases, the proportion of European clustering 
found in this project (43%) is probably only slightly (<3%) 
overestimated.
A  high  proportion  (55%)  of  genotyped  MDR  TB 
strains belonged to the Beijing genotype family. Strains of 
the Beijing genotype family were mainly reported for case-
patients originating from the Baltic states and other FSU 
countries, where the prevalence of this genotype is also 
high in the general population (12). The 3 largest clusters 
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Table 4. Predictors for clustered MDR TB strains compared with unique strains among 521 cases reported in 16 European countries,
January 2003 through June 2007* 
MDR TB strains 
Variable No. patients  % Clustered 
Unadjusted OR (95% CI)  Adjusted† OR (95% CI) 
Sex 
  Male  347 48 1 1
  Female  170 49 1.0 (0.7–1.5)  1.1 (0.6–1.9) 
Age
  15–44  324 43 1 1
  45–64  143 61 2.1 (1.4–3.1)  1.3 (0.7–2.3) 
>65 36 53 1.5 (0.7–3.0)  2.8 (0.8–9.4) 
Origin 
  Baltic states  188 81 21.9 (10.6–44.9)  25.1 (9.9–64.0) 
  Other FSU countries‡  99 61 7.7 (3.7–16.1)  8.7 (3.2–23.2) 
  Other European countries  72 17 1 1
  Africa  71 24 1.6 (0.7–3.6)  1.1 (0.4–3.5) 
Site of disease 
  Pulmonary  473 50 2.4 (1.2–4.9)  0.5 (0.2–1.6) 
  Extrapulmonary  41 29 1 1
Previous TB 
  Yes  163 54 1.0 (0.6–1.4)  1.1 (0.6–1.9) 
  No  248 55 1 1
XDR TB 
  Yes  51 82 4.1 (1.9–8.7) _
  No 341 53 1 –
*TB, tuberculosis; MDR, multidrug-resistant; OR, odds ratio; CI, confidence interval; FSU, former Soviet Union; XDR, extensively drug-resistant. Boldface
indicates significance.  
†For all other factors in the model except XDR TB. 
‡Former Soviet Union countries: Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Ukraine, and Uzbekistan. RESEARCH
were characterized by strains of the Beijing genotype fam-
ily (84% of the clustered MDR TB cases).
Two hypotheses may explain the occurrence of the 
large clusters in Europe that were detected in this proj-
ect. The first hypothesis is direct person-to-person trans-
mission. This hypothesis can be verified by cluster in-
vestigation  of  the  cases  (by  using  contact-tracing  data 
if available) in countries with cases reported in clusters. 
Verifying that the isolates, especially of the largest clus-
ters, represent a single strain is important and can be done 
by contact investigations and application of an additional 
typing  method  such  as  the  newly  standardized  24-loci 
variable number tandem repeat (VNTR) typing (23). The 
second hypothesis is that genetically highly related strains 
are responsible for most MDR TB cases in Europe and 
that only a part of the cases in these clusters is associated 
with direct person-to-person transmission. In both sce-
narios, conditions could be improved by reinforcing case 
management (including healthcare access), following up 
on treatment (especially drug compliance), and increas-
ing social support. Adequate infection control measures 
should also be ensured in healthcare facilities. The sec-
ond scenario underlines that more fundamental research 
(including detailed research on DNA repair, fitness, and 
transmissibility) is needed to better understand changes 
in the bacterial population structure of TB, including the 
drug-susceptible  bacterial  population  and  the  ongoing 
evolutionary development of M. tuberculosis.
This study was limited by a lack of completeness of 
the genotyping information and, to a lesser extent, of epide-
miologic information. Data completeness varied by coun-
try. For some countries (Norway, the United Kingdom, the 
Netherlands, and Germany), the molecular data reported 
represent only a fraction of the molecular data available 
because these countries also used alternative DNA typing 
methods, which were not included in this project. Other 
countries have not yet implemented genotyping. Low data 
completeness in some countries could have affected the 
proportion of clustered versus unique strains, possibly in-
troducing a bias in the interpretation of the risk factor anal-
ysis. However, the proportion of MDR TB cases submitted 
with both epidemiologic and genotyping information from 
16 (68%) countries is promising, considering that IS6110 
RFLP  typing  is  technically  demanding.  This  proportion 
could probably be improved in the future with the imple-
mentation of the recently standardized VNTR typing (23). 
Another limitation of this study was that the identifica-
tion of MDR TB clusters was based on genotype cluster-
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Table 5. Predictors for TB caused by Beijing strains among 506 cases reported in 16 European countries, January 2003 through June
2007*
MDR TB strains 
Variable No. patients  % Beïjing strains  Unadjusted OR (95% CI)  Adjusted† OR (95% CI) 
Sex 
  Male  333 58 1 1
  Female  164 55 0.9 (0.6–1.3)  1.1 (0.5–2.4) 
Age
  15–44  313 53 1 1
  45–64  142 67 1.7 (1.1–2.6)  1.0 (0.5–2.1) 
>65 30 70 2.5 (1.1–5.5)  2.3 (0.5–10.4) 
Origin 
  Baltic states  188 92 154.5 (54.0–442.0) 173.8 (45.5–663.6)
  Other FSU countries‡  99 75 39.7 (14.4–109.5) 32.2 (8.6–120.8)
  Other European countries  71 6 1 1
  Africa  71 10 1.5 (0.4–4.9)  1.1 (0.2–5.5) 
Site of disease 
  Pulmonary  455 59 3.4 (1.7–6.6)  0.7 (0.1–3.3) 
  Extrapulmonary 40 30 1 1
Previous TB 
  Yes  156 64 1.1 (0.8–1.7)  1.0 (0.5–2.0) 
  No  245 62 1 1
Clustering
  Yes  250 87% 19.0 (12.0–30.3)  –
  No  250 26% 1
XDR TB 
  Yes  51 90 5.5 (2.1–14.3)  –
  No 341 62 1
*TB, tuberculosis; MDR, multidrug-resistant; OR, odds ratio; CI, confidence interval; FSU, former Soviet Union; XDR, extensively drug-resistant. Boldface
indicates significance.  
†For all other factors in the model except XDR TB. 
‡Former Soviet Union countries: Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Ukraine, and Uzbekistan. Clusters of MDR TB Cases, Europe 
ing. Therefore, person-to-person transmission could not be 
proven. Ideally, transmission dynamics should be confirmed 
by conventional contact investigations to link patients to 
contact persons (24). For the main clusters, EuroTB cor-
respondents (from the countries where these clusters have 
been identified) have received the identification numbers 
of the clustered MDR TB cases and were able to commu-
nicate with colleagues from other countries concerned by 
the same cluster and exchange information on case histo-
ries. However, for the largest MDR TB cluster (E0051), a 
special field investigation of cases would be necessary and 
would require international support and coordination. With 
the limitations of this study, the findings represented here 
may not be representative of all MDR TB cases in Europe.
MDR TB cases included in clusters should be inves-
tigated (including contact-tracing data) in countries where 
they  have  been  identified  to  increase  knowledge  about 
cross-border transmission of MDR TB and XDR TB and to 
identify routes of transmission and additional risk factors 
for these transmission pathways. The outputs of the investi-
gations will enable interventions that prevent further trans-
mission of MDR TB and XDR TB caused by increasing 
migration between European countries. Standards should 
be  developed  to  conduct  these  investigations,  including 
mechanisms to inform concerned national authorities when 
a molecular cluster is detected and a method for linking 
epidemiologic and genotyping data at the European level. 
Delays between diagnosis of MDR TB cases and cluster 
detection should be reduced to facilitate appropriate ac-
tions in the concerned countries and to avoid international 
transmission of these strains. International collaboration in 
cluster investigations should be encouraged
Results of this project are preliminary because data are 
not complete for all countries. Since March 2008, Euro-
pean surveillance of MDR TB has been undertaken by the 
European Centre for Disease Prevention and Control. A 
molecular component has been added in this surveillance 
program. Ideally, this project should be extended to other 
European Union countries and neighboring countries that 
could provide genotyping data.
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